| 104.46 -1.19 (-1.13%) | 11-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 127.63 | 1-year : | 149.08 |
| Resists | First : | 109.27 | Second : | 127.63 |
| Pivot price | 104.86 |
|||
| Supports | First : | 93.66 | Second : | 84.01 |
| MAs | MA(5) : | 104.79  |
MA(20) : | 104.09 |
| MA(100) : | 86.63 |
MA(250) : | 74.97 |
|
| MACD | MACD : | 3.1 |
Signal : | 3.7 |
| %K %D | K(14,3) : | 54.7 |
D(3) : | 59.4 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 109.27 | Low : | 53.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INCY ] has closed above bottom band by 44.9%. Bollinger Bands are 21.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 107.12 - 107.55 | 107.55 - 107.91 |
| Low: | 103.9 - 104.43 | 104.43 - 104.89 |
| Close: | 104.75 - 105.6 | 105.6 - 106.33 |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Thu, 27 Nov 2025
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Thu, 27 Nov 2025
Incyte (INCY): Evaluating Valuation Following EMA Green Light for Minjuvi in Follicular Lymphoma - simplywall.st
Thu, 27 Nov 2025
Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY) - Seeking Alpha
Thu, 27 Nov 2025
Incyte: Riding Jakafi, Bracing For Generic Headwinds (NASDAQ:INCY) - Seeking Alpha
Tue, 25 Nov 2025
Incyte’s CAO Makes a Strategic Move with Stock Sale! - TipRanks
Tue, 25 Nov 2025
Barclays Sticks to Their Buy Rating for Incyte (INCY) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 196 (M) |
| Shares Float | 164 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 9,520 (K) |
| Shares Short P.Month | 8,500 (K) |
| EPS | 5.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.71 |
| Profit Margin | 24.7 % |
| Operating Margin | 31.6 % |
| Return on Assets (ttm) | 13.5 % |
| Return on Equity (ttm) | 30.3 % |
| Qtrly Rev. Growth | 20 % |
| Gross Profit (p.s.) | 13.85 |
| Sales Per Share | 24.5 |
| EBITDA (p.s.) | 6.72 |
| Qtrly Earnings Growth | 290.7 % |
| Operating Cash Flow | 1,250 (M) |
| Levered Free Cash Flow | 531 (M) |
| PE Ratio | 17.73 |
| PEG Ratio | 0 |
| Price to Book value | 4.4 |
| Price to Sales | 4.26 |
| Price to Cash Flow | 16.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|